However, ibrutinib, a tyrosine kinase inhibitor used for B-cell leukemias and lymphomas, is well-known to cause this problem.

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative ...

The global cell culture market is estimated to flourish at a CAGR of 9% from 2021 to 2031. Transparency Market Research projects that the overall sales revenue for cell culture is estimated to reach ...